Omega-3 polyunsaturated fatty acids (ɷ3 PUFA), have been proposed as a supplement to improve cardiometabolic risk factors in obese/overweight children and adolescents. However, findings evidence remains inconsistent. This meta-analysis aimed to assess the effects of ɷ-3 PUFA supplementation on cardiometabolic risk factors in obese/overweight children and adolescents. A systematic review of PubMed, Embase, Scopus, Web of Science, Cochrane Library, and Google Scholar up to January 2024 was searched. Data were pooled using a random-effects model to calculate Weighted mean differences (WMDs) and 95% Confidence intervals (CIs). Nine studies with 595 participants were included. The meta-analysis revealed that ɷ-3 PUFA supplementation significantly reduced Body mass index (BMI) (WMD = -0.39 kg/m²; 95% CI: -0.72, -0.05, I2 = 0.0%, P = 0.497), triglyceride (TG) (WMD = -23.54 mg/dl, 95% CI: -42.90, -4.18, I2 = 89.2%, P 1500 mg/ day) in term of BMI, LDL-c, TG. The quality of the included studies was assessed using the Cochrane risk-of-bias tool (RoB 2), which identified eight studies as having a high risk of bias. Additionally, the GRADE assessment indicated a high quality of evidence for BMI, HOMA-IR, TG and moderate quality for weight, FBS, TC, LDL-c, and HDL-c values. The current meta-analysis revealed that ɷ3 PUFA supplementation beneficial effect on BMI, HOMA-IR, and TG levels. No favorable effect of ɷ3 PUFA supplementation on weight, BMI z-score, TC, LDL-C, HDL-C, FBS and insulin was observed.
Musazadeh et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: